PEPG: Leerink Predicts Swift Resolution for PepGen’s Clinical Hold
Understanding the Recent FDA Clinical Hold on PepGen’s CONNECT2-EDO51 Study What Happened? PepGen recently announced that the FDA has placed a clinical hold on the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in Duchenne muscular dystrophy. This news has caused concern among investors and the medical community alike, as it raises questions about the future of…